Osstem Implant expands global sale of CA (Calcium SA) lineup

Search Dental Tribune

Osstem Implant expands global sale of CA (Calcium SA) lineup


The latest news in dentistry free of charge.

  • This field is for validation purposes and should be left unchanged.
Osstem Implant plans to gradually increase the CA lineup sale, especially in the countries in the Asia–Pacific region and South America, which are the emerging dental market.
Osteem Implant

By Osteem Implant

Wed. 23 November 2022


Osstem Implant Co., Ltd, a global enterprise with the world’s largest implant sales volume, announced that it will expand the sale of implant products with CA surface treatment technology applied through its local corporations in China, India, Vietnam, and Brazil.

Considering surface treatment is its key technology, Osstem Implant is equipped with over five surface treatment lineups, the largest in the implant industry. However, in the global market, with the exception of Korea, it has been mainly selling the SA (sand blasted with alumina and acid etching) lineup. This is because SA is the most universally applied surface treatment technique, and is also the most suitable product in the stage of overseas market development.


According to an analysis, the reason Osstem Implant decided to expand the global sale of the CA (calcium SA) lineup from the second half of this year is to show its advanced products to global customers and upgrade the brand image befitting the company’s growth trend. Osstem Implant plans to gradually increase the CA lineup sale, especially in the countries in the Asia–Pacific region and South America, which are the emerging dental market. 

CA surface treatment is Osstem Implant’s special packaging technique by which to submerge implants, for which SA surface treatment and cleaning process have been completed, into the calcium chloride (
CaCl2) solution. As CA ions in the calcium solution coat the implant surface, the binding between protein in the blood and the fixture is strengthened. In addition, platelet formation is accelerated to protect the surgical site. 


As a result, this technique improves hydrophilic and blood affinity of the implant, and reduces the patient’s treatment period by ensuring swift integration between the implant and the patient’s gum bones. Although it depends on the patient’s dental health conditions or bone mass, the average treatment period, assuming the strength of gum bones is average, is approximately four to six weeks. 


The effect of CA surface treatment to improve osseointegration ability was observed clearly in the in-vitro and in-vivo tests. In the in-vitro test, cell adhesion ability 3.5 times higher than that produced by the hydrophobic SA surface treatment was verified. As for cell proliferation, it improved by 33% in comparison to the existing surface treatment application. In addition, the activity of ALP, an enzyme secreted in the course of bone formation, was improved by 19%, and mineralization, which is to assess the degree of calcium ion deposition, also improved by 11%. 


In the in-vivo test, CA surface treatment was found to be superior to the existing surface treatment techniques by at least 24% in terms of BIC (bone to implant contact ratio), 8% in terms of BA (bone area), and 45% in terms of RT (removal torque). Therefore, CA surface treatment not only accelerates loading through fast bone formation but also contributes to minimizing the risk of early implant falling within the first three months by advancing the second stability improvement. In addition, a reduction in the risk of falling in the case of inferior bone quality or difficulties needing GBR and sinus bone graft can be expected. 


Osstem Implant’s CA lineup comprises TS, SS, and US systems. An Osstem Implant official said, “CA lineup with improved initial fixing and new bone generation ability from SA will be highly evaluated by not only clinicians, but also patients.”

For more information, visit en.osstem.com/glob

Leave a Reply

Your email address will not be published. Required fields are marked *